Merrill J T, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, Lahita R G, Salmon J, Cronstein B N
St. Luke's/Roosevelt Hospital Center, New York, New York 10019, USA.
Arthritis Rheum. 1997 Jul;40(7):1308-15. doi: 10.1002/1529-0131(199707)40:7<1308::AID-ART16>3.0.CO;2-M.
To determine why methotrexate (MTX) exacerbates rheumatoid nodules in some patients, despite the effective suppression of synovial inflammation.
Phorbol myristate acetate (PMA)-induced differentiation of monocytes into multinucleated giant cells was used as an in vitro model to study the effects of adenosine on nodulosis.
MTX at 200-2,000 nM or the adenosine A1 agonist N5-cyclopentyl adenosine (CPA) (10(-12) to 10(-9) M) or the A2 antagonist 3,7-dimethyl-1-propargylxanthine markedly enhanced giant cell formation, whereas the adenosine A1 antagonist 8-cyclopentyl-dipropylxanthine completely reversed these effects. PMA, CPA, and MTX induced adenosine release by cultured monocytes at concentrations consistent with those associated with predominantly A1 effects. Furthermore, surface expression of A1 receptors was found to remain unchanged on the differentiating cells throughout the culture period.
Agents that inhibit adenosine A1 receptors might be useful in the treatment of MTX-induced rheumatoid nodulosis, while still potentiating the A2-mediated antiinflammatory effects of MTX on synovitis.
确定为何甲氨蝶呤(MTX)在有效抑制滑膜炎症的情况下,仍会使一些患者的类风湿结节恶化。
以佛波醇肉豆蔻酸酯乙酸酯(PMA)诱导单核细胞分化为多核巨细胞作为体外模型,研究腺苷对结节形成的影响。
200 - 2000 nM的MTX、腺苷A1激动剂N5 - 环戊基腺苷(CPA)(10⁻¹²至10⁻⁹ M)或A2拮抗剂3,7 - 二甲基 - 1 - 丙炔基黄嘌呤均显著增强巨细胞形成,而腺苷A1拮抗剂8 - 环戊基 - 二丙基黄嘌呤则完全逆转这些作用。PMA、CPA和MTX诱导培养的单核细胞释放腺苷,其浓度与主要产生A1效应的浓度一致。此外,在整个培养期间,分化细胞上A1受体的表面表达保持不变。
抑制腺苷A1受体的药物可能有助于治疗MTX诱导的类风湿结节,同时仍能增强MTX对滑膜炎的A2介导的抗炎作用。